Aktualne aktualizacje dla Applied BioCode [6598.TW]

Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex diagnostic testing products for the In-Vitro diagnostics market. The company's products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the PCR amplification, hybridization, and detection steps of molecular testing; and the BioCode 2500 analyzer, a system that reads barcoded magnetic beads (BMB) and displays the barcode and fluorescence intensity for each BMB. In addition, It develops assays, such as BioCode SARS-CoV-2 Assay, a high volume automated nucleic acid multiplex assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; BioCode Respiratory Pathogen Panels, which simultaneously detects and differentiates the presence of 17 respiratory pathogens in nasopharyngeal swabs; BioCode gastrointestinal (GI) pathogen panels for common GI pathogens, including viruses, bacteria, and parasites that cause infectious diarrhea; and MDx assays pipeline for various molecular tests. Further, the company offers fungal pathogen analyte specific reagents; human cytokine/chemokine multiplex kits to identify relevant biomarkers; mouse premixed multiplex kits and custom panels for enhancing flexibility in experimental design allowing the user to pick and choose their own analytes panel; and rat, monkey, canine, and non-human primate cytokine/chemokine multiplex kits. Additionally, the company provides BMB, calibration beads, and coupling kits for various bioassay applications; ELISA, a tool for the quantitative measurement of drug/protein/antibody levels in biological samples comprising cell lysate or serum; and various assay development services. Applied BioCode Corporation is based in Santa Fe Springs, California.